Special Issue

Peste des Petits Ruminants (PPR) Eradication: Improved Understanding of Epidemiology, Diagnostics and Vaccine Efficacy

Message from the Guest Editor

Throughout the developing world, the peste despetits ruminants (PPR) virus (PPRV) places a huge disease burden on agriculture, in particular affecting smallruminant production and contributing to poverty in many developing countries in Africa, the Middle East and Asia. A lack in the understanding of the key factors determining the transmission of the disease between species, host range, epidemiology and vaccine efficacy of PPRV poses a significant risk to the success of OIE and FAO's nascent PPR eradication campaign by 2030. Improving the understanding of the transmission dynamics, early events of pathogenesis, epidemiology, new diagnostics and vaccine efficacy and underlying the differential susceptibility of goats, cattle, pigs and wild species will broadly enhance our knowledge of disease spread, maintenance of virus in wildlife and cattle and host-specific disease-resistance mechanisms. Therefore, this Special Issue is aimed to have a great impact on PPR eradication.

Guest Editor

Prof. Dr. Satya Parida

Laboratory and Vaccine Specialist, Food and Agriculture Organization of the United Nations, Rome, Italy

Deadline for manuscript submissions

closed (30 November 2020)



Viruses

an Open Access Journal by MDPI

Impact Factor 3.5 CiteScore 7.7 Indexed in PubMed



mdpi.com/si/28572

Viruses
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
viruses@mdpi.com

mdpi.com/journal/ viruses





Viruses

an Open Access Journal by MDPI

Impact Factor 3.5 CiteScore 7.7 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

You are invited to contribute a research article or a comprehensive review for consideration and publication in *Viruses* (ISSN 1999-4915). *Viruses* is published in open access format—research articles, reviews and other content are released on the internet immediately after acceptance. The scientific community and the general public have unlimited free access to the content as soon as it is published. As an open access journal, *Viruses* is supported by the authors or their institutes by payment of article processing charges (APC) for accepted papers. We would be pleased to welcome you as one of our authors.

Editor-in-Chief

Dr. Eric O. Freed

HIV Dynamics and Replication Program, Center for Cancer Research, National Cancer Institute, Frederick, MD 21702-1201, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Embase, PubAg, and other databases.

Journal Rank:

JCR - Q2 (Virology) / CiteScore - Q1 (Virology/Infectious Diseases)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.6 days after submission; acceptance to publication is undertaken in 2.5 days (median values for papers published in this journal in the first half of 2025).

